Cargando…

One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology

OBJECTIVE: The aim was to study the effect of non-mandatory transitioning from etanercept originator to etanercept biosimilar on retention rates in a setting promoting shared decision-making. METHODS: In 2016, all patients treated with etanercept originator and stable disease at the Rheumatology dep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müskens, Wieland D, Rongen-van Dartel, Sanne A A, Teerenstra, Steven, Adang, Eddy M M, van Riel, Piet L C M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519774/ https://www.ncbi.nlm.nih.gov/pubmed/33005860 http://dx.doi.org/10.1093/rap/rkaa042

Ejemplares similares

Biosimilars in the management of chronic inflammatory diseases: The Dutch experience
por: Müskens, Wieland D., et al.
Publicado: (2019)

Telemedicine in the management of rheumatoid arthritis: maintaining disease control with less health-care utilization
por: Müskens, Wieland D, et al.
Publicado: (2021)

Patients’ experiences regarding self-monitoring of the disease course: an observational pilot study in patients with inflammatory rheumatic diseases at a rheumatology outpatient clinic in The Netherlands
por: Renskers, Lisanne, et al.
Publicado: (2020)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Exercise participation has increased in patients with Rheumatoid Arthritis: A cross-sectional comparison between two Dutch RA cohorts
por: Weijers, Julia M., et al.
Publicado: (2018)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2020)

Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

The changing landscape of biosimilars in rheumatology
por: Dörner, Thomas, et al.
Publicado: (2016)

Exploring healthcare professionals’ knowledge, attitudes and experiences of shared decision making in rheumatology
por: Mathijssen, Elke G E, et al.
Publicado: (2020)

Effect of significant weight loss on disease activity: reason to implement this non-pharmaceutical intervention in daily clinical practice
por: Weijers, Julia M, et al.
Publicado: (2021)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Physicochemical Characterization of Altebrel™, a Proposed Etanercept Biosimilar
por: Fazel, Ramin, et al.
Publicado: (2019)

Biosimilars in rheumatology: understanding the rigor of their development
por: Goel, Niti, et al.
Publicado: (2017)

Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
por: Thiele, Franz, et al.
Publicado: (2021)

The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland
por: Luukkanen, Saana V., et al.
Publicado: (2022)

Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
por: Di Giuseppe, Daniela, et al.
Publicado: (2021)

Biosimilars in rheumatology: what the clinician should know
por: Castañeda-Hernández, Gilberto, et al.
Publicado: (2015)

Era of biosimilars in rheumatology: reshaping the healthcare environment
por: Smolen, Josef S, et al.
Publicado: (2019)

Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study
por: Larid, Guillaume, et al.
Publicado: (2022)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2016)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm
por: Schulze-Koops, Hendrik, et al.
Publicado: (2017)

Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries
por: El Zorkany, Bassel, et al.
Publicado: (2018)

Effectiveness and cost effectiveness of interpersonal community psychiatric treatment (ICPT) for people with long-term severe non-psychotic mental disorders: a multi-Centre randomized controlled trial
por: van Veen, Mark, et al.
Publicado: (2021)

Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry
por: Manders, Sofie H M, et al.
Publicado: (2015)

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting
por: Moorkens, Evelien, et al.
Publicado: (2019)

Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis
por: Lindström, Ulf, et al.
Publicado: (2019)

Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
por: Hassett, Brian, et al.
Publicado: (2018)

Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study
por: Carballo, Nuria, et al.
Publicado: (2022)

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
por: Fleischmann, Roy, et al.
Publicado: (2020)

Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
por: Mysler, Eduardo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gkruma08kjnqs3fdejks4lp1u7